Loading...

Home
ETF
06160

06160

-

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

Overview Technical News

Most Trusted AI Platform for Winning Trades

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

Home
Contact
About Us
Press
Privacy
Terms of Service
Service Terms of Use

Resources

Blog
Tutorial
Help Center
Affiliate Program

Markets

Market Analysis
Crypto
Featured Screeners
AI Earnings Calendar
Market Movers
Stock Monitor
Economic Calendar
All US Stocks
All Cryptos

Tools

Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator

Features

QuantAI Alpha Pick
SwingMax Portfolio
Swing Trading
AI Stock Picker
Whales Auto Tracker
Daytrading Center
Patterns Detection
AI Screener
Financial AI Agent
Backtesting Playground
AI Earnings Prediction
Stock Monitor
Technical Analysis

News

Overview
Top News
Daily Market Brief
Earnings Analysis
Newswire
Stock News
Crypto News
Institution News
Congress News
Monitor News

Compare

TradingView
SeekingAlpha

06160 News

CLSA Lowers BEONE MEDICINES (06160.HK) Price Target to $286.2 Following 4Q25 Net Profit Disappointment

Mar 03 2026aastocks

CICC Identifies Possible 'Blue Chip' Stocks for HSI Semi-Annual Adjustment Predictions (Table)

Jan 19 2026aastocks

CICC Forecasts Inclusion of ZIJIN GOLD INTL, BEONE MEDICINES, PICC P&C, and AKESO in HSI; STANCHART Likely to Take HANG SENG BANK's Place

Jan 19 2026aastocks

BEONE MEDICINES' 'Baiyue Da' Achieves First Sales Transaction in Beijing

Jan 15 2026aastocks

HSI Rises 123 Points at Opening; Pharmaceutical Stocks Surge; HAIDILAO Jumps Over 5%

Jan 14 2026aastocks

HKEX Introduces Six New Classes of Stock Options

Jan 09 2026aastocks

BeOne Reports ZIIHERA Trial Results, Significant Survival Improvement Observed

Jan 06 2026Businesswire

BeOne Medicines to Present at 2026 J.P. Morgan Healthcare Conference

Dec 23 2025Yahoo Finance

China's NRDL Set to Launch Next Year; BEONE MEDICINES Secures Two Drugs on Shortlist

Dec 08 2025aastocks

BeOne Medicines Presents 52.4% Efficacy of Sonrotoclax at ASH Meeting

Dec 07 2025Businesswire

BeOne's Sonrotoclax Shows Significant Efficacy in MCL and CLL Treatments

Dec 07 2025Newsfilter

BeOne Medicines' Sonrotoclax Receives FDA Priority Review for R/R MCL Treatment

Nov 26 2025Newsfilter

<Midday Update> HSI Falls 340 Points; HSTI Declines 131 Points; BABA Drops More Than 3%; WH GROUP and BOSIDENG Reach New Peaks

Nov 14 2025aastocks

CICC Increases BEONE MEDICINES' Target Price to HKD250; Maintains Outperform Rating

Nov 13 2025aastocks

<Research> BOCOMI Increases Price Target for BEONE MEDICINES (06160.HK) to $231 Following Promising New Pipeline Developments

Nov 11 2025aastocks

CCBI Raises BEONE MEDICINES (06160.HK) Price Target to $234 Following Strong 3Q Results, Maintains Outperform Rating

Nov 10 2025aastocks